Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

MDR-001

Stage Phase 3Stale

Sponsor MindRank AI Ltd

Route oral

Class Small molecule

Mechanism oral small molecule

Sources

registry, as of 2025-12-22Stale

https://clinicaltrials.gov/study/NCT07274137

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor MindRank AI Ltd. Enrollment 738. Conditions Overweight or Obesity. This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal

ClinicalTrials.gov NCT07274137 protocol and results modules

registry, as of 2024-09-24Stale

https://clinicaltrials.gov/study/NCT06606483

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight. Overall status UNKNOWN. Phases PHASE2. Lead sponsor MindRank AI Ltd. Enrollment 300. Conditions Obesity; Overweight and Obesity. This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesit

ClinicalTrials.gov NCT06606483 protocol and results modules

registry, as of 2026-09-18Stale

https://clinicaltrials.gov/study/NCT06778850

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor MindRank AI Ltd. Enrollment 128. Conditions Overweight and Obese Volunteers. To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.

ClinicalTrials.gov NCT06778850 protocol and results modules

registry, as of 2025-08-08Stale

https://clinicaltrials.gov/study/NCT07110766

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor MindRank AI Ltd. Enrollment 24. Conditions Obesity &Amp; Overweight. This is a 12 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase Ib trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity

ClinicalTrials.gov NCT07110766 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07274137

placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MD

NCT07274137 description or intervention text

Studies

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)

Registry NCT07274137

Phase Phase 3

Status Not yet recruiting

Enrollment 738

MDR-001 Dose 1

Comparator placebo

Population Overweight or Obesity

MDR-001 Dose 2

Comparator placebo

Population Overweight or Obesity

placebo

Population Overweight or Obesity

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Registry NCT06606483

Phase Phase 2

Enrollment 300

Start 2024-09-23

Primary completion 2025-07-30

Study completion 2025-09-30

Catalyst Primary completion. 2025-07-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

90 mg MDR-001

Dose 90 mg

Comparator placebo

Population Obesity; Overweight and Obesity

120 mg MDR-001

Dose 120 mg

Comparator placebo

Population Obesity; Overweight and Obesity

150 mg MDR-001

Dose 150 mg

Comparator placebo

Population Obesity; Overweight and Obesity

180 mg MDR-001

Dose 180 mg

Comparator placebo

Population Obesity; Overweight and Obesity

placebo

Population Obesity; Overweight and Obesity

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

Registry NCT06778850

Phase Phase 1/2

Status Completed

Enrollment 128

Start 2023-06-09

Primary completion 2024-07-15

Study completion 2024-09-30

MDR-001(SAD)

Comparator placebo

Population Overweight and Obese Volunteers

Placebo (SAD)

Population Overweight and Obese Volunteers

MDR-001 (MAD)

Comparator placebo

Population Overweight and Obese Volunteers

Placebo (MAD)

Population Overweight and Obese Volunteers

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

Registry NCT07110766

Phase Phase 1

Status Not yet recruiting

Enrollment 24

Start 2025-08-09

Primary completion 2025-09-15

Study completion 2025-10-30

Catalyst Primary completion. 2025-09-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

MDR-001

Comparator placebo

Population Obesity &Amp; Overweight

Placebo

Population Obesity &Amp; Overweight